financetom
Business
financetom
/
Business
/
Seagate Technology Poised for Re-Rating, Positive Earnings Revisions Amid Near-Term Catalysts, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Seagate Technology Poised for Re-Rating, Positive Earnings Revisions Amid Near-Term Catalysts, Morgan Stanley Says
Feb 27, 2025 9:54 AM

12:16 PM EST, 02/27/2025 (MT Newswires) -- Seagate Technology ( STX ) could see potential structural re-rating, multiple expansion, and positive earnings per share revisions in the coming months as near-term catalysts for the company build-up, Morgan Stanley said in a Thursday note.

Morgan Stanley's latest industry and supply chain checks confirm that hard disk drive demand continues to outstrip supply, with production lead times remaining elongated at 52 weeks and like-for-like pricing increasing quarter-over-quarter.

In addition, a stronger cloud capex outlook, which has been revised $50 billion higher in the past 1.5 months, further supports HDD demand and reinforces Seagate's ( STX ) revenue growth trajectory, according to the note.

The investment firm expects Seagate ( STX ) to grow revenue, margins, EPS, and free cash flow sequentially through 2025, driving both positive earnings revisions and a valuation re-rating. Another key catalyst is Seagate's ( STX ) May 22 Analyst Day, where Morgan Stanley anticipates the company will issue above-consensus long-term growth and margin guidance.

Despite recent market concerns around DeepSeek, Morgan Stanley believes the market has mispriced Seagate ( STX ), arguing that greater AI adoption will increase demand for data storage and retention rather than weaken it, further strengthening the HDD cycle.

Morgan Stanley raised its price target on Seagate Technology ( STX ) stock to $138 from $134, with an overweight rating.

Additionally, the firm reiterated Seagate ( STX ) as its Top Pick in IT hardware.

Price: 101.83, Change: +1.56, Percent Change: +1.56

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Inspirato Shareholder Stoney Lonesome Slams Buyerlink Merger, Urges Board to Consider Rival Bid
BRIEF-Inspirato Shareholder Stoney Lonesome Slams Buyerlink Merger, Urges Board to Consider Rival Bid
Sep 10, 2025
Sept 10 (Reuters) - Inspirato Inc ( ISPO ): * INSPIRATO SHAREHOLDER STONEY LONESOME: RELEASES PUBLIC LETTER REGARDING ITS STRONG OPPOSITION TO BUYERLINK MERGER * STONEY LONESOME HF LP: URGES INSPIRATO TO IMMEDIATELY ENGAGE WITH EXCLUSIVE INVESTMENTS FOLLOWING ITS $3.15 PER SHARE ALL-CASH OFFER * STONEY LONESOME HF LP: OWNS APPROXIMATELY 5.4% OF INSPIRATO INCORPORATED Source text: Further company coverage:...
Joby to bring helicopter and seaplane rides to Uber app as soon as 2026
Joby to bring helicopter and seaplane rides to Uber app as soon as 2026
Sep 10, 2025
(Reuters) -Air-taxi maker Joby Aviation said on Wednesday that it planned to bring Blade's helicopter and seaplane services to the Uber app as soon as next year. Joby acquired Blade Air Mobility's passenger business in August for up to $125 million, and plans to use the helicopter ride-share firm's infrastructure to launch its own electric air taxi service globally in...
Synopsys Shares Fall Pre-Bell Amid Job Cut Plans
Synopsys Shares Fall Pre-Bell Amid Job Cut Plans
Sep 10, 2025
08:03 AM EDT, 09/10/2025 (MT Newswires) -- Synopsys ( SNPS ) shares fell more than 23% in Wednesday's premarket activity after the company announced plans to reduce its headcount by 10%. The announcement was made by CEO Sassine Ghazi in a call with analysts on Tuesday. We will continue harnessing AI efficiencies to optimize our cost structure, he said, according...
Waldencast Says FDA Approves its Obagi Saypha MagIQ Hyaluronic Acid Gel
Waldencast Says FDA Approves its Obagi Saypha MagIQ Hyaluronic Acid Gel
Sep 10, 2025
08:02 AM EDT, 09/10/2025 (MT Newswires) -- Waldencast ( WALD ) said Wednesday that the US Food and Drug Administration has approved its Obagi saypha MagIQ, an injectable hyaluronic acid gel. The company said it will launch the product in the US next year. Waldencast ( WALD ) said a pivotal trial of 270 patients over 48 weeks met primary...
Copyright 2023-2026 - www.financetom.com All Rights Reserved